

Patient Population

Inclusion:

- Stage 4 or 5 CKD patients undergoing HD with planned primary de novo AVF

Exclusion:

- non primary AVF creation or revision.
- medical indication for anti-platelet agents or known intolerance of agents.



Stratification

- upper vs. lower arm site
- study centre



RANDOMISATION



ARM A

Aspirin & Omega-3 fatty acids



ARM B

Aspirin placebo and **Omega-3 fatty acids**



ARM C

Aspirin and Omega-3 fatty acids placebo



ARM D

Aspirin placebo & Omega-3 fatty acids placebo



Endpoints

Primary Endpoint: - patency of AVF at 84 days post creation

Secondary Endpoints: - functional patency of AVF at 6 & 12 months post creation
- primary patency time
- secondary patency time